Global Typhoid
Fever Vaccines Market, by Vaccine Type (Live Attenuated Vaccine, Capsular
Polysaccharide Vaccines, Conjugate Vaccine, and Others), by Typhoid Fever
Vaccines Type (Oral and Parental), and by Region (North America, Latin America,
Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 225.0 Mn in
2018, and is projected to exhibit a CAGR of 11.9% during the forecast period
(2018–2026).
Increasing government initiatives
for rising awareness regarding typhoid vaccines and supporting access to new
vaccines are expected to support the global typhoid fever vaccines market
growth. Active involvement by organizations such as GAVI Alliance (Global
Alliance for Vaccines and Immunisation), UNICEF (The United Nations
International Children's Emergency Fund), WHO (World Health Orginization), and
others in increasing accessibility of these vaccines in emerging economies is
further expected to fuel typhoid fever vaccines market growth.
For instance, in April 2018, Gavi
designated US$ 85 million to fund introduction of Typbar TCV (Bharat Biotech)
vaccine in low-income countries across Africa and Asia region. Moreover, there
are several typhoid conjugate vaccines present in the pipeline, which are
expected to enter in the market over the forecast period. In October 2017,
WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) re-emphasized
the importance of typhoid vaccines in low- and middle-income countries, as well
as for the control of endemic typhoid. Moreover, the Typhoid Vaccine
Acceleration Consortium (TyVAC), which is a partnership between University of
Maryland School of Medicine, University of Oxford and PATH, is currently
conducting clinical trials for Typbar TCV prequalified vaccine in Malawi,
Nepal, and Bangladesh to further evaluate clinical efficacy and potential of
the vaccine in reducing typhoid burden in these countries.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2552
Furthermore, introduction of
clinically more effective typhoid vaccines in private markets (such as India)
as well as internationally has supported growth of the market. For instance,
Vivotif (oral vaccine), clinically more effective Typhim Vi (WHO prequalified
in 2011), and now Typbar TCV (first conjugate vaccine WHO prequalified in 2017)
are now available in the market
Browse 26 Market Data Tables and
25 Figures spread through 177 Pages and in-depth TOC on Global Typhoid Fever
Vaccines Market By Vaccine Type (Live Attenuated Vaccine, Capsular
Polysaccharide Vaccines, Conjugate Vaccine, and Others), by Typhoid Fever
Vaccines Type (Oral and Parental), and Region (North America, Latin America,
Europe, Asia Pacific, the Middle East, and Africa) - Global Forecast to 2026
Efficient antibiotic treatment
can reduce the fatality rate of typhoid to less than 1%. However, recent past
has witnessed an increase in antimicrobial resistance of Salmonella Typhi. For
instance, according to the Typhoid Vaccine Acceleration Consortium (TyVAC),
which is a partnership between University of Maryland School of Medicine,
University of Oxford and PATH, by 2014, 97% of registered typhoid cases in
Malawi have resisted treatment from multiple antibiotics. As per the same
source, the antibiotic resistant typhoid cases are increasing globally. In
relation to this, in 2015, the World Health Assembly (WHA) started a global
action plan to tackle drug resistance, which focuses on prevention,
surveillance, and research of antibiotic resistance. Moreover, the Wellcome
Trust and current surveillance projects, including Surveillance for Enteric
Fever in Asia Project (SEAP) and Severe Typhoid Fever Surveillance in Africa
(SETA) are conducting research to identify typhoid drug-resistance trends and
monitor antibiotic use across South Asia and sub-Saharan Africa This is
expected to shift the attention towards diseases prevention rather than cure,
which in turn will have positive impact on increasing immunization efforts.
This, along with all the other drivers (disease prevalence, increasing
government support, initiatives, and product launches) is expected to support
growth of the market over the forecast period
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/typhoid-fever-vaccines-market-2552
Key Takeaways of the Typhoid
Fever Vaccines Market:
The global typhoid fever vaccines
market is expected to exhibit a CAGR of 11.9% during the forecast period (2018
– 2026), owing to frequent product launches and approvals, and robust pipeline
of novel typhoid fever vaccines
Asia Pacific typhoid fever
vaccines market is expected to account for largest market share, owing to high
prevalence of typhoid fever. For instance, according to the data published by
Medindia around 18,45,997 cases of typhoid were found in India in 2015
North America typhoid fever
vaccines market is expected to show stagnant growth over the forecast period,
owing to low prevalence of typhoid in region. For instance, according to the data
published by Centers of Disease Control and Prevention (CDC) 2017, around 300
culture-confirmed cases of typhoid fever and 80 cases of paratyphoid fever
caused by S. enterica serotype Paratyphi A are reported annually in the U.S.
Major players operating in the
typhoid fever vaccines market include GlaxoSmithKline Plc., Sanofi SA, Bharat
Biotech, Bio-Med Pvt. Ltd., PT Bio Farma, PaxVax, Inc. Shanghai Institute of
Biological Products Co., Ltd., and Prokarium
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2552
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment